Cargando…

Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial

BACKGROUND: To assess whether patients with Persistent Depressive Disorder (PDD) have abnormal levels of N-acetyl-aspartate (NAA) and whether those levels normalize following treatment with the antidepressant medication duloxetine. Furthermore, we conducted post hoc analyses of other important brain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bansal, Ravi, Hellerstein, David J., Sawardekar, Siddhant, O’Neill, Joseph, Peterson, Bradley S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641507/ https://www.ncbi.nlm.nih.gov/pubmed/31323045 http://dx.doi.org/10.1371/journal.pone.0219679

Ejemplares similares

Neonatal brain metabolite concentrations: Associations with age, sex, and developmental outcomes
por: Merz, Emily C., et al.
Publicado: (2020)

Association of Prenatal Sugar Consumption with Newborn Brain Tissue Organization
por: Berger, Paige K., et al.
Publicado: (2021)

Maternal prenatal immune activation associated with brain tissue microstructure and metabolite concentrations in newborn infants
por: Spann, Marisa N., et al.
Publicado: (2023)

Evidence for Neuroplastic Compensation in the Cerebral Cortex of Persons with Depressive Illness
por: Bansal, Ravi, et al.
Publicado: (2017)

Serotonin–norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials
por: Yang, Jie, et al.
Publicado: (2022)

Aberrant hippocampus and amygdala morphology associated with cognitive deficits in schizophrenia
por: Peterson, Bradley S., et al.
Publicado: (2023)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Morphological Biomarkers in the Amygdala and Hippocampus of Children and Adults at High Familial Risk for Depression
por: Peterson, Bradley S., et al.
Publicado: (2022)

Associations of Human Milk Oligosaccharides with Infant Brain Tissue Organization and Regional Blood Flow at 1 Month of Age
por: Berger, Paige K., et al.
Publicado: (2022)

The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis
por: Lozano, Patricia A., et al.
Publicado: (2022)

Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?
por: Greer, Tracy L., et al.
Publicado: (2014)

Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study
por: Cheon, Eun-Jin, et al.
Publicado: (2016)

Duloxetine in the treatment of major depressive disorder: an open-label study
por: Hudson, James I, et al.
Publicado: (2007)

Duloxetine-Induced Liver Injury in Patients with Major Depressive Disorder
por: Kang, Seung-Gul, et al.
Publicado: (2011)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
por: Norman, Trevor R, et al.
Publicado: (2010)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
por: Cui, Zhanglin, et al.
Publicado: (2012)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
por: Muscatello, Maria Rosaria Anna, et al.
Publicado: (2019)

The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity
por: Kale, Pravin Popatrao, et al.
Publicado: (2014)

Cholestatic Jaundice Induced by Duloxetine in a Patient with Major Depressive Disorder
por: Park, Young-Min, et al.
Publicado: (2010)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
por: Ye, Wenyu, et al.
Publicado: (2011)

Depression Treatment with Duloxetine and Reduction of Inability to Work
por: Happich, Michael, et al.
Publicado: (2012)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

The role of duloxetine in the treatment of anxiety disorders
por: De Berardis, Domenico, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Norman, Trevor R, et al.
Publicado: (2008)

Duloxetine in the treatment of generalized anxiety disorder
por: Wright, Alan, et al.
Publicado: (2009)

Influence of antidepressants on plasma levels of nitric oxide metabolites in patients with major depressive disorder
por: Ikenouchi, Atsuko, et al.
Publicado: (2021)

The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
por: Lee, Min-Soo, et al.
Publicado: (2012)

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
por: Fu, Cynthia HY, et al.
Publicado: (2015)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
por: Sun, Ching-Fang, et al.
Publicado: (2019)

Attributes of response in depressed patients switched to treatment with duloxetine
por: Sagman, D, et al.
Publicado: (2011)

Duloxetine in panic disorder with somatic gastric pain
por: Preve, Matteo, et al.
Publicado: (2013)

Influence of antidepressants on plasma levels of nitric oxide metabolites in patients with major depressive disorder – RETRACTION
por: Ikenouchi, Atsuko, et al.
Publicado: (2022)

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
por: Mallinckrodt, Craig H, et al.
Publicado: (2005)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada, Eiji, et al.
Publicado: (2016)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder
por: Zhu, Junliang, et al.
Publicado: (2022)

Duloxetine for the treatment of generalized anxiety disorder: a review
por: Khan, Ahsan Y, et al.
Publicado: (2009)

Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second‐generation antidepressants: Study protocol for a randomized, parallel‐group, non‐inferiority trial
por: Yokoi, Yuma, et al.
Publicado: (2019)

Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy
por: Kim-Romo, Dawn N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3f66no76g3cu3t3bal6klquoqv